The billion-dollar problem keeping Ozempic, Wegovy, and Zepbound from patients

ScienceDaily Health

Ozempic, Wegovy, and similar drugs may deliver excellent health value, but covering them for millions of eligible patients could overwhelm insurance budgets.

Researchers say better long-term support is needed and warn that low-cost compounded versions may carry serious safety risks. ...

전문 보기

이 뉴스, 어떠셨어요?

탭 한 번으로 반응 · 로그인 불필요

The billion-dollar problem keeping Ozempic, Wegovy, and Zepbound from patients

이 뉴스, 어떠셨어요?

관련 뉴스

'science' 카테고리 뉴스

Spontaneous changes in brain state influence the readiness to form memories, neuroscientists find

Cutting out the noise: How horseshoe bats adapt their echolocation behavior in colonies

Native fine-flavor cacao can match commercial varieties in yield, study finds

ScienceDaily의 다른 기사

AI helps Stanford scientists discover “natural Ozempic” without the usual side effects

Scientists discover a compound that could supercharge aging muscle repair

A new antiviral could stop measles before an outbreak takes off